Growth Strategy for Analytical & Measuring Instruments Business
Growth Strategy for Analytical & Measuring Instruments Business Read more
Category: Uncategorized
QIAGEN reports preliminary Q3 2019 results and announces measures to prioritize resource allocation
Preliminary Q3 2019 sales of about 3% CER growth (vs.~4-5% CER outlook), adjusted EPS in line with outlook Initiatives announced to free up resources to invest in best growth opportunities, in particular new partnership with Illumina in NGS clinical decision-making Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today... Read more
Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation (3)
Venlo, The Netherlands, October 07, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces preliminary sales results for the third quarter of 2019 fall short of expectations. For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the... Read more
Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation (2)
Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Peer M. Schatz, Chief Executive Officer, has notified the Company that he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Advisor to the Supervisory Board... Read more
Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation
Venlo, The Netherlands, October 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces measures to prioritize resource allocation to the most attractive growth opportunities in its Sample to Insight portfolio, in particular in light of a new orientation for its next-generation sequencing (NGS) activities. The measures to free up resources comes... Read more
Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Basel, 27 September 2019 Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data will be shared with health authorities... Read more
Luminex Corporation to Present at the Cantor Global Healthcare Conference on October 2, 2019
AUSTIN, Texas, Sept. 26, 2019 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, President and Chief Executive Officer, and Harriss Currie, Senior Vice President of Finance and CFO, will participate in investor meetings and present at the Cantor Global Healthcare Conference on Wednesday, October 2, 2019 in New York, NY. A live... Read more
Nalgene Outdoor Applauds Quick-Thinking of Hikers and Rescuers in “Message in a Bottle” Rescue
Nalgene Outdoor Applauds Quick-Thinking of Hikers and Rescuers in “Message in a Bottle” Rescue ROCHESTER, N.Y., Sept. 13, 2019 /PRNewswire/ — Nalgene Outdoor, manufacturers of the original water bottle that traces its roots back to 1949, applauds the search and rescue workers and quick-thinking of Curtis Whitson who used an SOS message in a Nalgene... Read more
Detecting Sperm on Washed Textiles
Application note on light microscopy in forensic analyses The ability to identify spermatozoa is a particularly important technique in forensic science, for example within the scope of solving sexual crimes. A suspected perpetrator’s sperm needs to be detected on the victim’s clothing and identified through the use of a specific test. This is achieved, for... Read more
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Basel, 06 September 2019 European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung... Read more